Clinical trials: Cervix Neoplasms
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
METASTATIC CERVICAL CANCER
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy…
- Trial name
- NCT05446883
- Testing
- QL1706, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 498 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Sarcoma, Melanoma
A Study of PRT1419 in Patients With Advanced Solid Tumors
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer
- Trial name
- NCT04837677
- Testing
- PRT1419
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Prelude Therapeutics Incorporated
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) .
- Trial name
- NCT03786107
- Testing
- Almac HER-Seq Assay
- Where
- 22 sites in United States, France and 5 more
- Volunteers
- 1,583 people
- Sponsor
- Puma Biotechnology, Inc.
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old…
- Trial name
- NCT01381575
- Testing
- GSK Biologicals' HPV vaccine 580299
- Where
- 33 sites in Canada, Germany and 3 more
- Volunteers
- 1,447 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colposcopy
Investigation of the Uterine Cervix Using CervicalMD
The purpose of this study is to demonstrate the CervicalMD device's ability to collect digital imagery suitable for a colposcopy examination.
- Trial name
- NCT00839475
- Volunteers
- 26 people
- Sponsor
- STI-Medical Systems
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Cervical Cancer
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
This study is a multi-center, prospective, open-label, single-arm phase II clinical study to evaluate the efficacy, safety and immunogenicity of GB226 in treatment of recurrent or metastatic cervical cancer patients with PD-L1…
- Trial name
- NCT03808857
- Testing
- GB226
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Genor Biopharma Co., Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT07602842
- Testing
- IDP-001
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- InduPro, Inc.
Cancer of Cervix
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant…
- Trial name
- NCT00191100
- Testing
- Gemcitabine, Cisplatin, Brachytherapy
- Where
- 7 sites in Argentina, Bosnia and Herzegovina and 5 more
- Volunteers
- 515 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Cervical Cancer
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent…
- Trial name
- IVOLGA (NCT06943833)
- Testing
- Volrustomig
- Where
- 12 sites in Russia
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Gynecologic Cancer, Cancer Metastatic
Study of AK112 in the Treatment of Advanced Gynecological Tumors
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
- Conditions
- Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm
- Trial name
- NCT04870177
- Testing
- AK112
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Akeso
HPV Infection, Lesion Cervix
Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.
Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix…
- Trial name
- PAPILOBS (NCT04199260)
- Testing
- papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 263 people
- Sponsor
- Procare Health Iberia S.L.
Cervical Cancer
Biop System's Safety and Performance
Biop system's safety and performance in increased detection of High-Grade lesions of the cervical epithelium in women scheduled for colposcopy
- Trial name
- NCT04232865
- Testing
- Biop System
- Volunteers
- 320 people
- Sponsor
- BIOP Medical
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Esophageal Cancer, Gastric Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
- Conditions
- Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
- Trial name
- NCT05438420
- Testing
- Q702, Pembrolizumab
- Where
- 7 sites in United States, South Korea
- Volunteers
- 120 people
- Sponsor
- Qurient Co., Ltd.